Hepatocellular carcinoma treatments, prophylactic therapies, and compositions
undiscloseddrug program · medium · Wed Nov 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop therapies, prophylactic therapies, and compositions for cancers including hepatocellular carcinoma.
Patent-described therapeutic processes, methods, systems, and compositions for treating various cancers including hepatocellular carcinoma.
US patent application US20240075108A1 was published on 2024-03-07 and is listed as assigned to Repair Biotechnologies, Inc. on 2025-11-12 in the supplied patent record.
Atherosclerosis CDP Therapy
preclinicaldrug program · high
Reverse atherosclerotic plaque by reducing excess cholesterol in affected arterial cells.
Therapy based on the Cholesterol Degrading Platform to degrade toxic free cholesterol inside cells and rapidly reduce arterial plaque.
Company states 'We reverse atherosclerosis' and describes atherosclerosis as the initial focus of its CDP therapy.
Atherosclerosis Program
preclinicaldrug program · high
Reverse atherosclerotic plaque by reducing excess cholesterol in targeted cells.
Therapeutic application of the Cholesterol Degrading Platform, described as cholesterol degradation using LNP-mRNA and gene therapy approaches.
Listed in the company pipeline as an initial focus of the Cholesterol Degrading Platform.
Cholesterol Degrading Platform
preclinicalplatform · high
Treat medical conditions caused by localized accumulations of excess cholesterol, with a lead focus on rapidly reducing atherosclerotic plaque and addressing cholesterol-driven cardiovascular disease; public excerpts also mention familial hypercholesterolemia and liver fibrosis in metabolic disorders.
Platform approach that breaks down toxic free cholesterol inside cells; described as adaptable to multiple indications and delivery mechanisms.
Company describes the platform as first-in-class and focused on atherosclerosis/plaque regression; public pipeline lists REP-0003 as the named program.
Company description states treatments can rapidly and dramatically reduce atherosclerotic plaque in arteries.
HoFH mRNA Therapy
preclinicaldrug program · medium
Treat homozygous familial hypercholesterolemia, including accelerated atherosclerotic disease, by addressing excess cellular cholesterol.
mRNA therapy based on Repair Biotechnologies' cholesterol-degrading approach.
FDA granted RDEP eligibility for Repair Biotechnologies' mRNA therapy for HoFH, and the company plans to open an IND application for continued FDA collaboration.
Homozygous Familial Hypercholesterolemia Program
preclinicaldrug program · high
Address accelerated atherosclerotic disease in homozygous familial hypercholesterolemia by reducing excess cholesterol burden.
Therapeutic application of the Cholesterol Degrading Platform.
Listed in the company pipeline as a focus area connected to accelerated atherosclerosis in HoFH.
MASH CDP Therapy
preclinicaldrug program · medium
Treat metabolic-dysfunction associated steatohepatitis and related liver fibrosis in metabolic disorders by reducing cholesterol-driven pathology.
Cholesterol Degrading Platform therapy intended to reverse liver fibrosis in metabolic disorders.
MASH is listed as a potential pipeline application of the Cholesterol Degrading Platform.
Metabolic-dysfunction Associated Steatohepatitis Program
preclinicaldrug program · medium
Treat a cholesterol-driven liver condition by degrading excess cholesterol in targeted cells.
Potential application of the Cholesterol Degrading Platform to MASH.
Listed in the company pipeline as a potential application of the platform.
REP-0003
preclinicaldrug program · high
Develop an mRNA therapeutic for Homozygous Familial Hypercholesterolemia and cholesterol-driven disease by degrading excess intracellular cholesterol, with intended effects including arterial plaque reduction.
mRNA therapeutic based on Repair Biotechnologies' Cholesterol Degrading Platform.
Listed on the company pipeline; public record title states FDA granted RDEP eligibility for Repair Biotechnologies' mRNA therapy for HoFH, and another public excerpt states the company plans to open an IND application for continued FDA collaboration.
Preclinical atherosclerotic plaque regression data are referenced, but no quantitative results are supplied.
Undisclosed Liver Indication
undiscloseddrug program · medium
Address an undisclosed liver disease or condition connected to cholesterol-driven pathology.
Undisclosed application of the Cholesterol Degrading Platform.
Listed in the supplied pipeline as an undisclosed liver indication.
